Vanda Pharmaceuticals | VNDA - Assets


Vanda Pharmaceuticals reported $488.95M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Akebia Therapeutics USD 342.13M 7.53M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Insmed USD 2.23B 123.49M Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
Ligand Pharmaceuticals USD 2.24B 51.59M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Moderna USD 13.47B 2.51B Sep/2026
Novartis USD 117.15B 1.38B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 130.29B 1.23B Sep/2026
Takeda JPY 15.27T 391.77B Sep/2026
Teva Pharmaceutical Industries USD 40.04B 185M Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Veracyte USD 1.57B 86.89M Sep/2026